Ixekizumab Medicine 09 January 2018 Extended indication Psoriatic Arthritis. Therapeutic value Possible equal value Total cost € 7,875,000.00 Registration phase Unknown Product Active substance Ixekizumab Domain Chronic immune diseases Reason of inclusion Main indication Skin diseases Extended indication Psoriatic Arthritis. Current proprietary name Already available biosimilars / generics Proprietary name Taltz Manufacturer Eli Lilly Portfolio holder Mechanism of action Unknown Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Vergelijkbaar met secukinumab. Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date Expected Registration February 2018 Orphan drug No Registration phase Unknown Reimbursement Medicine sluice Additional remarks Indicatie-uitbreiding. Positieve opinie CHMP december 2017 Therapeutic value Current treatment options Vergelijkbaar met secukinumab en beter dan abatacept. Therapeutic value Possible equal value This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 18 times a year Dosage per administration 80 mg References Nash et al, Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24.; Mease et al, Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Additional remarks Twee injecties van 160 mg eenmaal, dan 80 mg om de 2 weken voor 12 weken, dan 80 mg om de vier weken. Onbeperkte behandeling. Expected patient volume per year Patient volume 300 - 600 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Verwacht 600 patiënten die in aanmerking komen voor behandeling met een anti-IL17 geneesmiddel, en dit zal woren gedeeld tussen secukinumab, ixekizumab, en later ook brodalimumab. Expected cost per patient per year Cost € 15,000.00 - 20,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Medicijnkosten.nl; Fabrikant Additional remarks Gelijke kosten vergeleken met secukinumab, meerkosten vergeleken bij andere biologische geneesmiddelen voor zelfde indicatie. €1151,16 per 80 mg. Volgens behandelschema 18x per jaar komt neer op € 20.720,88 pppj. Fabrikant: €14.118 voor onderhoudsdosering (obv 13 pennen per jaar en huidige AIP). €18.462 prijs inductie jaar (obv max 17 pennen per jaar en huidige AIP). Potential total cost per year Total cost € 7,875,000.00 Total cost for sluice Additional remarks Off label use Off label use No Indications off label use References Additional remarks Indication extension Indication extensions Yes Indication extensions Spondyloartritis, waarschijnlijk in 2019. References Additional remarks Other information Additional remarks